Reproterol


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Acute bronchospasm 10-20 mg 3 times/day. Inhalation Acute bronchospasm Per inhalation of metered-dose aerosol contains 500 mcg: 1-2 inhalations 3-6 hrly as needed. IV Status asthmaticus 90 mcg, may repeat after 10 mins if needed.
Dosage Details
Inhalation/Respiratory
Acute bronchospasm
Adult: As metered-dose aerosol containing 500 mcg/inhalation: 1 or 2 inhalations, repeated every 3-6 hr as required.

Intravenous
Status asthmaticus
Adult: 90 mcg via slow IV inj, may repeat after 10 minutes if needed.

Oral
Acute bronchospasm
Adult: As hydrochloride: 10-20 mg tid.
Child: As hydrochloride: As metered-dose aerosol: 6-12 yr: 1 inhalation (500 mcg) every 3-6 hr.
Contraindications
Hypertrophic obstructive cardiomyopathy, tachyarrhythmia, phaechromocytoma, hypersensitivity.
Special Precautions
Hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation, hypertension, severe asthma and diabetes mellitus. Monitor plasma potassium concentrations. Pregnancy and lactation.
Adverse Reactions
Fine tremor of skeletal muscle, palpitations, muscle cramps, tachycardia, nervous tension, headache, peripheral vasodilatation, hypersensitivity reactions.
Potentially Fatal: Large doses may result in severe hypokalaemia.
Drug Interactions
Increased risk of hypokalaemia when used with potassium-depleting drugs eg. corticosteroids, diuretics and theophylline. May enhance neuromuscular blockade produced by pancuronium and vecuronium. Increased risk of digitalis-induced arrhythmias.
Action
Description: Reproterol is a direct-acting sympathomimetic with predominantly β-adrenergic activity and a selective action on β2-receptors.
Disclaimer: This information is independently developed by MIMS based on Reproterol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in